BAXTER INTERNATIONAL to Lead Needle-Free IV Connectors Market from 2023-2030
January 27, 2023
Trending News 🌥️
The company has a wide portfolio of products and services, including drugs, biopharmaceuticals, infusion systems, and sterile injectables. A recent analysis of the Needle-free IV Connectors Market from 2023-2030 has revealed that BAXTER INTERNATIONAL ($NYSE:BAX) is expected to lead this market over the projected period. These connectors are used to reduce the risk of needle stick injuries and infections, reduce time spent connecting and disconnecting IV sets, and improve patient comfort. The company has a long history of developing and manufacturing high-quality medical products, including its SafeLink needle-free IV connector. This device is designed to reduce the risk of infection and injury by eliminating the need for needles or syringes.
In addition, it can be used with multiple types of IV solutions, including parenteral nutrition and medications. BAXTER INTERNATIONAL is also committed to providing a comprehensive range of services for healthcare providers, including customer support, technical assistance, training, and education. This commitment helps ensure that healthcare providers can safely and effectively use their products.
Share Price
Baxter International has long been a leader in the healthcare industry, and on Monday the company announced that it will be taking an even larger role in the needle-free IV connectors market. The stock opened at $44.0 and closed at $45.1, an increase of 2.9% from its previous closing price of $43.9. Baxter International’s needle-free IV connectors are designed to provide a safe and hygienic alternative to traditional IV lines, which are prone to infections and other complications. The needle-free connectors feature a one-way valve that prevents fluid from entering the catheter, as well as a secure locking mechanism that prevents accidental disconnection. Baxter’s connectors also come with a variety of adapters that make it easy to attach to any existing IV system. The company’s commitment to the needle-free IV connectors market is further evidenced by its investment in research and development. Baxter has invested heavily in its team of engineers, scientists, and clinicians to develop leading-edge technologies that will allow them to stay ahead of the competition.
Additionally, Baxter is also working with other leading healthcare companies to help develop innovative products that will further reduce complications associated with IV lines. The needle-free IV connectors market is expected to continue to grow in the coming years, and Baxter International’s leadership position in this market will help them maintain their competitive edge. With its commitment to research and development, Baxter is well-positioned to stay on top of the latest innovations in needle-free IV connectors and continue to deliver products that keep patients safe and healthcare providers efficient. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Baxter International. More…
| Total Revenues | Net Income | Net Margin |
| 14.74k | -2.38k | -4.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Baxter International. More…
| Operations | Investing | Financing |
| 1.47k | -10.94k | 7.96k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Baxter International. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 27.96k | 22.39k | 10.98 |
Key Ratios Snapshot
Some of the financial key ratios for Baxter International are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.6% | -18.1% | -13.1% |
| FCF Margin | ROE | ROA |
| 5.1% | -16.7% | -4.3% |
VI Analysis
Investors looking for long-term potential should take a close look at Baxter International‘s fundamentals. The VI Star Chart shows that the company is strong in dividends and profitability, medium in growth, and weak in assets. In terms of overall health, Baxter International has a score of 8/10 when it comes to cashflows and debt, indicating that it is well-positioned to sustain future operations in times of crisis. Furthermore, the company is classified as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors interested in such companies typically focus on the potential for large returns without too much risk. Short-term investors can benefit from the high-growth potential of these companies, while those investing for the long-term may be more interested in the stability of their profits. In summary, Baxter International has strong fundamentals, a high health score, and a ‘cheetah’ profile, making it an attractive option for investors looking for long-term potential. Its growth potential and relatively low risk make it an ideal choice for those looking to invest in the long run. More…
VI Peers
Baxter International Inc is a large medical device company. Its main competitors are Utah Medical Products Inc, Clarity Medical Group Holding Ltd, and Merit Medical Systems Inc.
– Utah Medical Products Inc ($NASDAQ:UTMD)
The company’s market cap is $313.74 million and its ROE is 11.43%. Utah Medical Products, Inc. engages in the design, manufacture, and marketing of medical devices. It operates through the following segments: Pregnancy & Newborn, Patient Care, and Animal Health. The Pregnancy & Newborn segment offers a line of products used by obstetricians, gynecologists, and neonatal caregivers for the health and well-being of pregnant women and their babies. The Patient Care segment provides a line of products used by hospitals, clinics, and home healthcare providers for the treatment of respiratory and other conditions. The Animal Health segment offers a line of products used by veterinarians for the health and well-being of animals.
– Clarity Medical Group Holding Ltd ($SEHK:01406)
According to Clarity Medical Group Holding Ltd’s market cap as of 2022, the company is worth 599.47 million. Clarity Medical Group Holding Ltd is a Medical Group that provides healthcare services. The company was founded in 2014 and is headquartered in Hong Kong.
– Merit Medical Systems Inc ($NASDAQ:MMSI)
Medstronic is a medical device company that manufactures and sells a variety of medical devices and equipment. The company has a market cap of 3.29B as of 2022 and a ROE of 5.86%. Medtronic’s products are used in a variety of medical procedures, including cardiac surgery, vascular surgery, and neurology.
Summary
Baxter International is well-positioned in the needle-free IV connectors market, with a projected lead from 2023-2030. Baxter offers a variety of products and services including drug delivery, dialysis and hospital products. Investors should consider Baxter’s strong presence in the global healthcare market, as well as its commitment to research and development, to capitalize on the expected growth in the needle-free IV connectors market.
Baxter is also expanding its portfolio in order to meet the growing demand for needle-free IV connectors. Its focus on innovation and collaboration make the company an attractive long-term investment opportunity.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
